309 related articles for article (PubMed ID: 7986198)
1. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
Toffoli G; Simone F; Gigante M; Boiocchi M
Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
[TBL] [Abstract][Full Text] [Related]
2. Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines.
Toffoli G; Corona G; Simone F; Gigante M; De Angeli S; Boiocchi M
Int J Cancer; 1996 Jul; 67(1):129-37. PubMed ID: 8690513
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
4. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
Toffoli G; Corona G; Gigante M; Boiocchi M
Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
[TBL] [Abstract][Full Text] [Related]
6. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
7. Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.
Seidel A; Hasmann M; Löser R; Bunge A; Schaefer B; Herzig I; Steidtmann K; Dietel M
Virchows Arch; 1995; 426(3):249-56. PubMed ID: 7773504
[TBL] [Abstract][Full Text] [Related]
8. A synthetic triptycene bisquinone, which blocks nucleoside transport and induces DNA fragmentation, retains its cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
Wang B; Wu M; Perchellet EM; McIlvain CJ; Sperfslage BJ; Huang X; Tamura M; Stephany HA; Hua DH; Perchellet JP
Int J Oncol; 2001 Dec; 19(6):1169-78. PubMed ID: 11713586
[TBL] [Abstract][Full Text] [Related]
9. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
10. Synthetic 1,4-anthracenediones, which block nucleoside transport and induce DNA fragmentation, retain their cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
Wu M; Wang B; Perchellet EM; Sperfslage BJ; Stephany HA; Hua DH; Perchellet JP
Anticancer Drugs; 2001 Nov; 12(10):807-19. PubMed ID: 11707648
[TBL] [Abstract][Full Text] [Related]
11. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
[TBL] [Abstract][Full Text] [Related]
12. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
Consoli U; Priebe W; Ling YH; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M
Blood; 1996 Jul; 88(2):633-44. PubMed ID: 8695811
[TBL] [Abstract][Full Text] [Related]
13. D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.
Damiani D; Michieli M; Michelutti A; Melli C; Cerno M; Baccarani M
Anticancer Drugs; 1993 Apr; 4(2):173-80. PubMed ID: 8098233
[TBL] [Abstract][Full Text] [Related]
14. Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells.
Meschini S; Calcabrini A; Monti E; Del Bufalo D; Stringaro A; Dolfini E; Arancia G
Int J Cancer; 2000 Sep; 87(5):615-28. PubMed ID: 10925353
[TBL] [Abstract][Full Text] [Related]
15. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells.
Lacayo NJ; Duran GE; Sikic BI
J Exp Ther Oncol; 2003; 3(3):127-35. PubMed ID: 14641819
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship of verapamil analogs and reversal of multidrug resistance.
Toffoli G; Simone F; Corona G; Raschack M; Cappelletto B; Gigante M; Boiocchi M
Biochem Pharmacol; 1995 Oct; 50(8):1245-55. PubMed ID: 7488241
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein but not topoisomerase II and glutathione-S-transferase-pi accounts for enhanced intracellular drug-resistance in LoVo MDR human cell lines.
Boiocchi M; Tumiotto L; Giannini F; Viel A; Biscontin G; Sartor F; Toffoli G
Tumori; 1992 Jun; 78(3):159-66. PubMed ID: 1359686
[TBL] [Abstract][Full Text] [Related]
18. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
[TBL] [Abstract][Full Text] [Related]
19. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.
Lotfi K; Zackrisson AL; Peterson C
Cancer Lett; 2002 Apr; 178(2):141-9. PubMed ID: 11867198
[TBL] [Abstract][Full Text] [Related]
20. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
Michieli M; Damiani D; Michelutti A; Candoni A; Masolini P; Scaggiante B; Quadrifoglio F; Baccarani M
Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]